Drugs / CKD-386(3)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05245084 | Mar → Jun 2022 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-386(3) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245084 ↗ |
| Route | Oral | “A single oral dose of 1 tablet under fasting condition” NCT05245084 ↗ |